

**inno.N**  
(KS.195940)

# Investor Presentation



Homepage → <https://www.inno-n.com>



Mail → [IR@inno-n.com](mailto:IR@inno-n.com)



Official TELEGRAM



This material were prepared for the convenience of investors, without an external auditor's review being completed, and some of the contents are subject to change after the final audit by an external auditor.

This presentation may contain forward-looking statements based on current assumptions and forecasts made by HK inno.N. Various known and unknown risks, uncertainties and other factors could lead to material differences between the actual future results, financial situation, development or performance of the company and the estimates given here.

The company assumes no liability whatsoever to update these forward-looking statements or to adjust them to future events or developments.


innovate  
New & Next

## ▀ Company Overview

Core Business – ETC / H&B / R&D


# Company Overview

## Kolmar Korea Group



## Shareholders

As of Sep 30, 2024



1) Employee Stock Ownership Association

# Corporate Identity

Full-fledged growth into a global pharmaceutical company



The background features a world map with a light gray background. A blue logo 'inno.N' is centered over the Korean peninsula. Numerous thin, curved blue lines radiate from the logo to various locations across the globe, including North America, South America, Europe, Africa, and Asia. There are also several blue circular markers placed at these global locations, representing a worldwide network or distribution system.

**inno.N**

Blockbuster Drug Developer

KR's 30th Novel Drug  
K-CAB®

Target to penetrate  
K-CAB in 100 Countries

45 countries  
As of 2024

New IV Plant  
Expansion('2022~)

Largest Capacity in KR  
105mn bags/yr

Megabrand  
Condition®

KR's No.1 (M/S 43%)  
Hangover relieving Drink

R&D Pipeline

GLP-1 receptor agonist,  
JAK inhibitor

Initiatives

UNGC (UN Global Compact)



HK inno.N joined UNGC in October of 2021 and ever since has been submitting an annual report (COP) on how it has implemented the 10 principles of UNGC in its business operations.

K-RE100 (Korean version of RE100)



RE 100 is a global renewable energy initiative aiming to have power generated using environment-friendly and renewable energy sources, such as through photovoltaic power or wind power, make up 100% of the electric power demanded.

Since joining the Korean version of RE 100, often referred to as K-RE 100, in 2023, HK inno.N has been implementing detailed programs to have 100% of its energy needs met through renewable energy sources by year 2050.

ESG Ratings



| Year | Total |
|------|-------|
| 2023 | BBB   |



| Year | Total | E | S  | G  |
|------|-------|---|----|----|
| 2024 | A+    | A | A+ | A+ |
| 2023 | A     | A | A+ | A  |




| Year   | Asset Size | Total |
|--------|------------|-------|
| 1H2024 | AA         | AA    |
| 2H2023 | AA         | AA    |
| 1H2023 | AA         | AA    |

# Business Performance

Rapid sales growth since launch of K-CAB['19~'23 sales CAGR : 8.8%]

(Unit : USD mn)

ETC H&B Operating profit



• K-CAB launched  
\*30th Korean novel drug


• Beauty business initiated

• Rapid growth of K-CAB  
• MSD vaccine introduced

• Global milestones  
• IV new plant operated

• K-CAB finished products exported  
• Even growth of all IV products

499  
YoY  
+9.3%



3Q24

- ✓ Change in K-CAB co-promotion contract  
→ Significant increase in SALES / OP
- ✓ Cardiovascular & Diabetic drug expansion

ETC  
(90%)

- Ethical drug lineup in more than 7 treatment areas (cardiovascular, gastrointestinal, diabetes/kidney, anticancer, etc.)
- Essential medicines for national basic medical care and disaster preparedness, such as IV and vaccines



H&B  
(10%)

- Health: hangover relieving drink, healthcare beverage
- Beauty: hair loss care, cosmetics



Company Overview



**Core Business – ETC / H&B / R&D**




# ETC – Business Status

## Continuous Rapid Growth via K-CAB / IV Significant Profitability Improvement from 2024

### Sales trend

(Unit : USD mn)

■ IV ■ Cardiovascular ■ Diabetes/Kidney ■ Gastrointestinal ■ MSD vaccine ■ Others



### Major achievements

**1 Continuous K-CAB Growth(5<sup>th</sup> year since launch)**  
USD 26 mn in sales('19) → USD 90 mn in sales('23)

**2 Additional growth momentum via new Osong IV plant**  
Production capacity Expansion  
: 50 mn bags per a year → 105 mn bags per a year


**3 Strengthening cardiovascular and diabetes portfolios And improving profitability**  
Sales of 4 types of Kanarb family, Xigduo, etc. from 2024

### Operating profit and margin ratio trend

(Unit : USD mn)

■ Operating profit


○ Margin ratio







# K-CAB® : Next Generation A2B Drug

## Unparalleled advantages over PPI / H2RA and other competing P-CAB drugs

### Market positioning




### Overview of K-CAB

|  |  |
|--|--|
|  <b>5</b> Indications   | Gastric acid related diseases (EE, NERD, GU, Maintenance treatment, H. pylori infection)           |
|  <b>4</b> Formulations | 50mg tablet / 50mg orally disintegrating tablet<br>25mg tablet / 25mg orally disintegrating tablet |
|  Patent Term          | Substance patent(valid till Aug '31),<br>Crystalline form patent(valid till Mar '36)               |
|  Market Size          | Global <sup>5)</sup> : USD 16 bn<br>Domestic <sup>6)</sup> : USD 879 mn                            |

### Onset Time <sup>7)</sup>


**Fastest**  
3<sup>rd</sup> gen

**Tegoprazan (K-CAB / P-CAB)**  
\* Inno.N (KOR) / launched in '19



2<sup>nd</sup> gen


**Esomeprazole (PPI)**



3<sup>rd</sup> gen

**Vonoprazan (P-CAB)**


\* TAKEDA (JPN) / launched in '15



3<sup>rd</sup> gen

**Fexuprazan (P-CAB)**

\* Daewoong (KOR) / launched in '22



Source: Company data, UBIST data, BCC Research

Note: 1) H2 Receptor Antagonist 2) Proton Pump Inhibitor 3) Potassium-Competitive Acid Blockers 4) Nocturnal Acid Breakthrough 5) BCC data 6) '22 Ubist data 7) [CJ\_APA\_108] CSR of 2. Jenkins H, et al. Aliment Pharmacol Ther. 2015;41(7):636-648 3. Sunwoo J, et al. Aliment Pharmacol Ther. 2018;48(2):206-218;

# K-CAB® : Shortest time to reach 100mn in sales, unrivaled No.1 A2B Drug

Launched in  
**Mar, 2019**

**Co-Promotion with**  
Boryung  
(Jan 2024~)

Accumulated prescription  
sales


**USD 504mn**

Prescription performance  
exceeded **USD 14mn** on  
average per a month

**#1**

A2B drug since 3Q19  
(market size **USD 956mn**)

## TOP 5 A2B Drug (Unit : USD mn)




## UBIST Prescription result (Unit : USD mn)



# Domestic/Japanese A2B Market status


## Rapid switching phenomenon from PPIs to P-CABs in the A2B market

Domestic Market M/S (Unit : %)



Source : UBIST

Japanese Market M/S (Unit : USD mn)



Source : BCC Research


# K-CAB® : Global Strategy

Licensed Out to 45 countries including US and China → Marketing approval and launch in 17 countries

**License out to 100 countries by 2028**

**+100**

2028  
Countries



Source: Company data

Note : 1) National Reimbursement Drug List

# K-CAB® : Tech Transfer(China, USA)

## China Launch, US Phase III Clinical Trials



China



### 泰欣赞 (Taixinzan) launched, registered on NRDL<sup>1)</sup>

- L/O contract in 2015(Amount : USD 95mn)
- MA approval in Apr 2022 / Launched in May 2022
  - Listed as innovative new drug in China (1st class)
  - Indications : GERD, Duodenal ulcer, H. pylori infection
- Registered on NRDL, Mar 2023
- Global No.1 A2B market, 2nd largest pharmaceutical market
  - Chinese A2B market expected to reach USD 3.1 bn in 2021
- Injection(LX22001) clinical trials approved NMPA in June 2024

### NRDL registration to boost rapid growth in China

- Term : Mar 2023 ~ Dec 2024(Gradual registration by province)
- Registered in 31 provinces, sale activity and marketing commencement
- Market penetration via strong sales force and product competence
- Sales growth via high price and high volume

Note : 1) National Reimbursement Drug List



USA




### L/O Contract (Dec. 2021)

- Braintree Laboratories, a subsidiary of Sebel US Inc.  
(Amount : USD 540mn)

### Overview

- US pharmaceutical company with market leading position in Gastroenterology
- FDA approved Novel Drug [SUTAB('21), SUFLAVE('23)]
- net sales ~\$150m, driven by market leading colon prep
- Covering 94% of US Gastroenterology provider



### R&D Pipeline Progress

| Indication                            | Stage     |         |             |                |              |
|---------------------------------------|-----------|---------|-------------|----------------|--------------|
|                                       | Phase 1   | Phase 2 | Phase 3     | NDA Submission | FDA Approval |
| Erosive esophagitis<br>(n=1,250)      | Completed | SKIP    | In Progress | Planned        | Planned      |
| Non erosive reflux disease<br>(n=800) | Completed | SKIP    | Completed   | Planned        | Planned      |

Source: Sebel Corporate Presentation (2024), Clinicaltrials.gov


# K-CAB® : Finished Product Exports

## Global Launch and Sales Initiation via Marketing Authorization Approval

K-CAB finished product export countries

| Lan | Region          | Country  | Launch                                  |
|-----|-----------------|--|---|
| 1   | -               |  Mongolia             | Oct 2022                                |
| 2   | South-East Asia |  Philippines          | Nov 2022                                |
| 3   |                 |  Indonesia            | Jul 2023                                |
| 4   |                 |  Singapore            | Aug 2023                                |
| 5   |                 |  Malaysia             | <u>Marketing authorization approved</u> |
| 6   |                 |  Thailand             |   |
| 7   | South America   |  Mexico               | May 2023                                |
| 8   |                 |  Peru                 | Oct 2023                                |
| 9   |                 |  Chile                | Aug 2024                                |
| 10  |                 |  Colombia           | Oct 2024                                |
| 11  |                 |  Dominican Republic | Nov 2024                                |
| 12  |                 |  Nicaragua          |   |
| 13  |                 |  Honduras           |   |
| 14  |                 |  Guatemala          |   |
| 15  |                 |  El Salvador        |   |

K-CAB finished product export sales trend (unit : USD mn)





# Strategic Partnership

Maximizing synergy through joint co-promotion between Korean Top-Class novel drugs



## Introduction of 4 types of Kanarb family from Boryung

- Kanarb, Korean 15<sup>th</sup> novel drug  
(Component : Fimasartan trihydrate)
- Introduction items : Kanarb, Dukaro, Dukarb,  
Dukarb Plus
- Prescription performance

: USD 90mn in 2022 → **USD 101mn in 2023**

(Source : UBIST)

## Co-Promotion Strategy

- Strengthening hypertension/dyslipidemia portfolios
- Expanding the prescription range for chronic diseases
- Maximizing growth potential between two novel drug  
by sharing blockbuster development capabilities




# Domestic IV Market Forecast

Sturdy 4% CAGR and steady demand  
fueled by in-patients and patients with severe conditions

## Domestic IV market

(Unit : USD mn)



Source: BCC Research  
Note: 1) Total parenteral nutrition

## Key growth drivers



### Increased usage of basic IV in in-patients

Higher growth rate than populations increase rate ('14-'19)  
Population: +0.4%, inpatients: +1.8%  
Usage of IV: +1.4%




### Increased TPN<sup>1)</sup> demand fueled by patients with severe conditions

Increase in usage of TPN<sup>1)</sup> from inpatients suffering from severe illnesses that rely on intravenous injection

# IV Business


Strengthen competitiveness via capacity expansion,  
TOP<sup>1)</sup> implementation and development of new TPN

IV sales (Unit : USD mn)



Operation of  
New IV plant  
(from June 2022)

Key progress



Note : 1) Twist-Off Protector

Company Overview



**Core Business** – ETC / **H&B** / R&D


# H&B (Health & Beauty) – Business Status

Well balanced portfolio consisting products with high profits  
(hangover relieving drink) & new business (beauty)

## Sales trend

(Unit : USD mn)

■ Condition ■ Hutgaesoo ■ Others




## Operating profit and margin ratio trend

(Unit : USD mn)

■ Operating profit

○ Margin ratio



## Major achievements

### 1 Hangover relieving drink (Condition)

- Sales increase(recovery) after lifting of social distancing restrictions
- Expansion of M/S of ND(Non-Drink : stick, hwan) product

### 2 Healthcare beverage

- Constant growth via release of new products and expansion of distribution networks
- Hutgaesoo, barley tea, carbonated water(REFREZ), liquid tea(tealog)

### 3 Beauty


- Lineup : 'bewants' eye serum stick, shampoo(Scalpmed)
- Expansion of bewants brand lineup
- Expansion of distribution network : H&B Store on/off channel(1,300 stores), Amazon US

# Condition, No.1 Hangover Relieving Drink


Condition - #1 in market share

New Market generation and market expansion with the launch of “Condition Stick”


Quarterly sales (Unit : USD mn)



Yearly sales (Unit : USD mn)



Condition M/S(Domestic)



Source : Company data, Nielsen IQ Korea data

## The Ministry of Food and Drug Safety announced [test guidelines for effectiveness of hangover relieving products]

- From Jan 1, 2025, the use of ‘hangover relieving’ phrase is only available when test results according to the guidelines are obtained, Condition’s market position is expected to be further strengthened.

## H&B\_Other Beverage

### Tealog (Zero calorie iced tea)

- Launched in 2023
- Sales in 2023 : USD 7mn



### Hutgaesoo (Liquid tea for thirst)

- Launched in 2010 / Sales in 2023 : USD 9mn




### Saessakbori (Liquid tea)

- Launched in 2015 / Sales in 2023 : USD 2mn



# H&B - Synergy with Kolmar

Swift entry into derma cosmetics market via accumulated pharmaceutical know-how and partnership with Kolmar (cosmetics ODM<sup>1)</sup>)



## Synergy with Kolmar

*Continuous portfolio diversification with aggressive branding*

### ScalpMed



Hair-loss prevention  
"Microbiome"  
technologies

### Be+wants



Patented "nymphoides indica"  
anti-aging, vegan-certified  
product

## Growth strategies

### Product line-up expansion

major brands  
**ScalpMed**  
**Be+wants**  
strategic development

### Channel expansion

- Expanding various channel networks such as H&B Store (on/off), Amazon US, etc

### Selective market penetration

- Prevention of hair loss
- Slow-aging Basic Line

Company Overview








**Core Business** – ETC / H&B / R&D



## R&D – Key pipeline

Operating R&D pipelines for synthetic new drugs, antibodies, and cell therapy  
in the areas of gastrointestinal, diabetes/obesity, autoimmune, infection, and oncology

| Development stage  | Candidate  | Pre-clinical  | P1  | P2                                    | P3  | Launch   |
|--|--|---|---|---------------------------------------|---|--|
|  Gastrointestinal | <div>Best-in-class</div> <div>First-in-class</div> |   | <b>B</b> IN-114199<br>CIC <sup>1)</sup>                                     | <b>F</b> FM-101<br>MASH <sup>2)</sup> |   | <b>C</b> K-CAB<br>GERD <sup>3)</sup> , Gastric Ulcer,<br>H. Pylori eradication |
|  Diabetes/Obesity  |  |   |   |                                       | <div>Planned</div> <div>IN-B00009</div> <div>GLP-1 Receptor Agonist</div> |  |
|  Autoimmune       | <b>B</b> 22ND01<br>TYK2 inhibitor                  |   | <b>B</b> IN-115314<br>AD <sup>4)</sup> , Psoriasis,<br>Rheumatoid arthritis |                                       | <b>B</b> IN-115314<br>Pet Atopic Dermatitis                               |  |
|  Infection       |  | <b>B</b> IN-B00001<br>Smallpox                          |   |                                       |   |  |
|  Oncology       | <b>F</b> IN-B00003<br>CAR-T/CAR-NK                 | <b>B</b> IN-119873<br>Next gen. EGFR <sup>5)</sup> inh. | <b>B</b> IN-B00004<br>CD56 NK (AML, MM)                                     |                                       |   |  |
|  | <b>F</b> IN-B00002<br>HLA-G MAB                    |   |   |                                       |   |  |

Source: Company data

Note: 1) Chronic idiopathic constipation; 2) Metabolic Dysfunction-Associated Steatohepatitis; 3) gastroesophageal reflux disease 4) Atopic dermatitis; 5) Epidermal growth factor receptor

# IN-B00009: Long-lasting Weekly Injection of GLP-1 Receptor Agonist

Significant decrease in HbA1C and body weight with comparable efficacy to semaglutide and tirzepatide

## Overview of Ecnoglutide

|                         |   |
|-------------------------|---|
| Target Indications      | Type 2 Diabetes, Obesity, MASH <sup>1)</sup>  |
| Dosage & Administration | Once a Week, Subcutaneous(SC) Injection   |
| Development Status      | P3 Clinical Studies for T2D/Obeisty in China are ongoing<br>* P1 in AUS / P2 in China and AUS/NZ / P3 in China conducted<br>* P3 for T2D/Obesity planned in KR  |
| Remarks                 | ❖ Clinically proven efficacy and safety which is comparable with semaglutide & tirzepatide<br>❖ Better cost-effectiveness than current competitors in market<br>❖ Potential development opportunity for FDC <sup>2)</sup> /oral formulation |



**Paradigm of T2D Treatment: GLP-1 RA<sup>3)</sup> is a Next-Generation Drug**



## Market Trends

- ❖ GLP-1 agonist market: reaching a global market size of \$105B in 2029
- ❖ Big pharmas are moving to combination of amylin analogue or DCRA<sup>4)</sup> as well as dual/triple agonist of incretin mimetics in clinical developments

Source: Company internal data, GlobalData, DataMonitor, ADA 2023\_poster


Note: 1) Metabolic dysfunction-associated steatohepatitis 2) Fixed-Dose Combination 3) Glucagon-like Peptide 1

4) Dual amylin and calcitonin receptor agonist

## Clinical Information


### HbA1c reduction (P2 in China)

Up to -2.39% HbA1c change at the end of treatment(134 Day)



### Body weight reduction at 26weeks(P2 in AUS/NZ)

Up to 14.7% BW loss after 26weeks of once-weekly dosing



# IN-115314: New topical JAK inhibitor for treatment of atopic dermatitis (AD)




Selectivity  
AD DNCB Model

ADME  
2/4/13 week repeat Tox (Rat, Monkey)  
8 week topical repeat Tox (Minipig)  
Genotoxicity  
Local Tox (Dermal, Eye)

## Phase 1: First-in-Human (Topical) study ongoing

|                         | Phase Ia  | Phase Ib  |
|-------------------------|---|---|
|                         | Single Ascending Dose (SAD)   | Multiple Ascending Dose (MAD)   |
| Target                  | Healthy volunteer (Korean)  | Healthy volunteer (Korean)  |
| Investigational product | IN-115314 ointment (5 doses)<br>Placebo                                 | IN-115314 ointment (2 doses)<br>Placebo                                 |
| No. of subjects         | 32  | 24  |
| Endpoint                | <ul style="list-style-type: none"><li>Safety</li><li>Exposure</li></ul> | <ul style="list-style-type: none"><li>Safety</li><li>Exposure</li></ul> |
| Duration                | 4M  | 4 M   |



SAD: Completion, MAD: Ongoing; Adevrse effect not reported

## Efficacy and safety of topical IN-115314 (pre-clinical)

### Growth of the global atopic dermatitis market : \$16B+ by 2027


- \$10B by 2019, CAGR 13% / Topical market: 25~30%
- 1<sup>st</sup> topical JAK inhibitor (Opzelura®): market sale \$400M by 2022.  
→ Topical market approx. doubles (US) / predicted peak sales \$1.8B  
→ Safety concerns by systemic exposure

### In vivo efficacy in mouse AD model

- DNCB-induced mouse AD model, Topical administration BID for 28 days
- ~50% improvement in dermatitis score and other skin parameters  
: IN-115314 ointment 3% ≥ tacrolimus 0.1% (TCI), delgocitinib 0.5% (JAKi)

### Topical JAK inhibitor, improves safety by minimizing systemic exposure

- No significant adverse effect was observed in Minipig 8-week repeated toxicity study.
- Compared to Opzelura®, improved safety by minimizing systemic exposure (Best in Class).



| Day                          | Dose     | AUC <sub>0-24hr</sub> (ng·h/mL) | Remark              |
|------------------------------|----------|---------------------------------|---------------------|
| Ruxolitinib cream (Opzelura) |          |                                 |                     |
| Day 296                      | 1.0% QD  | 79                              | WBC↓                |
|                              | 1.0% BID | 146                             | WBC↓ (dermal NOAEL) |
|                              | 1.5% BID | 198                             | WBC↓                |
| IN-115314 ointment           |          |                                 |                     |
| Day 56                       | 1% QD    | 1.44                            | -                   |
|                              | 3% QD    | 3.96                            | -                   |
|                              | 5% QD    | 21.97                           | - (NOAEL)           |

# IN-115314: New JAK inhibitor for treatment of canine atopic dermatitis (Pet HealthCare)




Selectivity  
AD HDM Model (mice)  
AD DNCB Model (mice)

PK-PD study in healthy dogs  
13-week repeated tox study in dogs  
Genotoxicity study  
Safety pharmacology study

HDM induced AD model in dogs  
IL-31 induced pruritus model in dogs

## PK/PD study in dogs




- Dose-dependent increase in exposure from 0.2 to 0.9 mg/kg.
- Dose-related PD effects on JAK1-related biomarker were confirmed.
- Effective dose of IN-115314 is considered to be similar to Apoquel®.

## Efficacy study in dogs

- HDM induced AD model in dogs: on-going
- IL-31 induced pruritus model in dogs: on-going

## Animal Health Sector Revenue Growth

### Annual Growth Rate & Shifts in Pets and Livestock




Source: Healthforanimals 2022

### JAK inhibitor as a Good Treatment Option for Canine Atopic Dermatitis

- Apoquel® (JAK inhibitor of Zoetis) sales was \$800 million in 2022.
- Skin disease including atopic dermatitis is the most common Vet visits (18%, CAGR 9% in Korea)

### Zoetis's AD Revenue (for Canine Use)\*



\*Apoquel (JAKi) + Cytopoint (IL-31 mab) for Canine AD

# IN-119873: Allosteric EGFR inhibitor, the best partner of Tagrisso®

The 4<sup>th</sup> Gen EGFR TKI for the treatment of L858R EGFR+NSCLC

Efficacy

GLP-Tox

Phase 1

Phase 2

Phase 3

Selectivity  
*in vitro* efficacy  
-L858R, L858R/T790M,  
L858R/C797S, L858R/T790M/C797S  
CDX model  
PDX model  
Brain metastasis *in vivo* model

## Competitive differentiation in the EGFR TKI Market

### The first allosteric EGFR inhibitor

- Excellent kinase selectivity without EGFR wild type activity
- Synergistic effect with osimertinib by unique allosteric binding mode
- Provide treatment options to Tagrisso® resistance patients.

### Great antitumor efficacy in patient derived xenograft

- High potential for demonstrating strong efficacy in human tumors

### Excellent antitumor efficacy in brain metastasis model

- Enhanced Competitiveness through improved antitumor efficacy in brain



## Development of 4<sup>th</sup> generation EGFR inhibitor compatible with 3<sup>rd</sup> generation TKI osimertinib combination

### Unmet medical needs


- Despite the approval of 3<sup>rd</sup>-generation EGFR inhibitors, patients with the L858R mutation exhibit a more unfavorable prognosis.
- There is currently no established standard 2<sup>nd</sup> line therapy following osimertinib treatment.
- The next-generation EGFR TKIs should address osimertinib resistance effectively, while avoiding EGFR WT activity to reduce issues like skin problems and cardiotoxicity.

### Development strategy

- Enhancing efficacy and minimizing through combination with 3<sup>rd</sup> generation EGFR TKI
- 4<sup>th</sup> generation EGFR inhibitor as the 2<sup>nd</sup> line treatment for non-responder to 3<sup>rd</sup> generation EGFR TKI drugs

### Forecast global market growth of EGFR TKI

- Growing and to reach \$6.8B by 2029 at CAGR 11%
- Global market growth of Osimertinib \$4.3B by '29 at CAGR 2.6 %
- The synergistic effect with osimertinib is expected to lead to the expansion of the market, potentially increasing the osimertinib market share.



### Global partnering opportunity

TKI: tyrosine kinase inhibitor; Tagrisso®(osimertinib): Standard of Care of NSCLC